PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

193	Substitute for form 1449A/PTO					Complete if Known			
						on Number	10/522		
	INFORMATION DISCLOSURE				Filing Date July 31, 2003		, 2003		
;	STATEMENT BY APPLICANT					ned Inventor	Vivian	I. TEICHBERG	
	(1	ıse as many sheets as nec	essary)		Art Unit 1615				
					Examine	Name	unknov	wn	
Sheet		1	of	3	Attorney	Docket Number	29147		
			U.S.	PATENT I	OCUMI	ENTS			
Examiner Cite Initials* No.		Document Number	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	Number-Kind Code ^{2 (if known)}								
	 -		ļ						
	 								
-			 					-	
	 		ļ						
	 	 			<u>-</u>				
	<u> </u>							·	
	 		 						
				-	-				
						· · · · · · · · · · · · · · · · · · ·			
		<u> </u>	L						
			FOREI	GN PATEN	T DOCL	JMENTS			
Examiner Initials*	Cite No. 1				ion Date	Name of Patentee	or	Pages, Columns, Lines, Where Relevant Passages T	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)		MM-DD-YY	D-YYYY	Applicant of Cited Document		Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6	
TG	1	PCT WO 99/21565	06-6-1999	Blass et al.			
						Ш	
	-						
				-		H	
Examine Signature		/Tiffany Gough/		Date Considered	05/18/200	6	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language

Trainstation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		Act of 1993, no persons are required to respond to a collection of information un	Complete:	
	Sui	bstitute for form 1449A/PTO	Application Number	10/522,415
	INE	ORMATION DISCLOSURE	Filing Date	July 31, 2003
STATEMENT BY APPLICANT			First Named Inventor	Vivian I.
				TEICHBERG
		(use as many sheets as necessary)	Group Art Unit Examiner Name	1615 unkown
Sheet	2	Of 3	Attorney Docket Number	29147
Silect	- 2 -			29147
		OTHER PRIOR ART – NON PATENT LITER	ATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the a item (book, magazine, journal, serial symposium, catalog, etc.) dai publisher, city and/or country where publisher, city and/or country where publisher.	te, page(s), volume-issue numb	of the er(s), T^2
TG	2	Matthews et al. "Enzymatic Degradation Protects Neur Excitotoxicity", Journal of Neurochemistry, 75(3): 104	ons From Glutamate	
	3	Jiang et al. "Glutamate Is A Principal Mediator of HIV	-1-Infected Immune	
ľ		Competent Human Macrophage Neurotoxicity", Societ	v for Neuroscience Abst	racts
		26(1-2), Abstract No. 136.17, 30th Annual Meeting of	the Society of Neuroscie	nce
		New Orleans, USA, 2000.	the society of neuroscie	nee,
	4	Di Giorgio et al. "Gabaergic Systems in Brain Regions	of Clutomata I paismad I	2-4-11
		Italien Journal of Biochemistry, 34(1): 19-28, 1985. P.	19, Line 15.	
	5	Engelhardt et al. "The Diagnostic Value of Enzyme De	termination in Cerebrosm	oinal
l •		Fluid", Medizinische Klinik, München, 71(17): 699-70	2. 1976. P.701.	
	6	Andrae et al. "Pyruvate and Related α-Ketoacids Protection		ulture
		Against Hydrogen Peroxide-Induced Cytotoxicity", To		
 		1985.		
l i	7	Avramis et al. "A Randomized Comparison of Native I	Escherichia Coli Asparag	inase
		and Polyethelyne Glycol Conjugated Asparaginase for	Treatment of Children W	/ith
		Newly Diagnosed Standard-Risk Acute Lymphoblastic	Leukemia: A Children's	
		Cancer Group Study", Blood, 99(6): 1986-1994, 2002.		
1	8	Cavallini et al. "The Protective Action of Pyruvate on I	Recovery of Ischemic Ra	t
		Heart: Comparison With Other Oxidizable Substrates",	Journal of Molecular Ce	:11
l		Cardiology, 22: 143-154, 1990.		
	9	Desagher et al. "Pyruvate Protects Neurons Against Hy	drogen Peroxide-Induced	1
1 1		Toxicity", The Journal of Neuroscience, 17(23): 9060-	9067, 1997.	
	10	Gramsbergen et al. "Pyruvate Protects Against 3-Nitro	propionic Acid Neurotox	icity
l i		in Corticostriatal Slice Cultures", Neuropharmacology,	11(21): 2743-2747, 2006	0.
	11	Hosoya et al. "Blood-Brain Barrier Produces Significar	t Efflux of L-Aspartic A	cid
	1	But Not D-Aspartic Acid: In Vivo Evidence Using the	Brain Effluy Index Meth	od"
		Journal of Neurochemistry, 73: 1206-1211, 1999.	Brain Emax macx with	°°',
	12	Lee et al. "Protection by Pyruvate Against Transient Fo	rehrain Isahamia in Data	,,
	'-	The Journal of Neuroscience, 21(RC171): 1-6, 2001.	neoraur ischennia in Kats	•
-	13	Liu et al. "P-Glycoprotein Regulated Transport of Glut	omata at Diand Dunia Da	
	1 '3	Acta Pharmacol Sin, 22(2): 111-116, 2001.	amate at Diood-Brain Ba	11161 ,
	14	Matsumoto et al. "Role of Pyruvate in Ischemia-Like C	landitions on Culture	
	1 4	Neurons", Neurological Research, 16: 460-464, 1994.	onations on Cultured	
 	15		stacts Applied Cl. 4	
	1.5	Matthews et al. "Glutamate-Pyruvate Transaminase Pro Toxicity in Hippocampal Slices", Brain Research, 978:		
	16	Matthews et al. "Enzymatic Degradation Protects Neur	one From Chitamata	
	1.0	Excitotoxicity", Journal of Neurochemistry, 75: 1045-1	ons rioni Giutamate 052-2000	1
 	17	Maus et al. "Pyruvate and Lactate Protect Striatal Neur	one Agginst NI Machail D	
	''	Aspartate-Induced Neurotoxicity", European Journal of	ons Agamsi N-Memyl-D	·-
		3224, 1999.	i meuroscience, 11: 3213	<u> </u>
	18	Mongan et al. "Pyruvate Improves Cerebral Metabolism	n During Hemograpaic	
		Shock", AJP - Heart and Circulatory Physiology, 281:	854-864, 2001	
	19	Mongan et al. "Intravenous Pyruvate Prolongs Survival	During Hemorrhagic Sh	ock
	1.7	in Swine", AJP - Heart and Circulatory Physiology, 27	7(46). H2252 H2262 10	00
	20	O'Kane et al. "Na+-Independent Glutamate Transporter	/(TU). 114433-114403, 19	77.
	20	EAAT3) of the Blood-Brain Barrier", The Journal of B	io (EAA I I, EAA I Z, and iological Chamistan, 224	(45).
TG		31891-31895, 1999.	iological Chemistry, 2/4	(42);
		1 21071-21072, 1777.		

6	TPEW		•	
n	EC 2 8 2085 H	21	Ruiz et al. "Protection by Pyruvate and Malate Against Glutamate-Mediated Neurotoxicity", NeuroReport, 9: 1277-1282, 1998.	
<u>,</u>	I.O.	22	Ryu et al. "Neuroprotective Effects of Pyruvate in the Quinolinic Acid Rat Model of Huntington's Disease", Experimental Neurology, 183: 700-704, 2003.	
1	TG	23	Steele "Blood-Brain Barrier Transport of the α-Keto Acid Analogs of Amino Acids", Federation Proceedings, 45(7): 2060-2064, 1986	
	TG	24	Stover et al. "Neurotransmitters in Cerebrospinal Fluid Reflect Pathological Activity", European Journal of Clinical Investigation, 27: 1038-1043, 1997.	
	TG	25	Wolff et al. "The Effectiveness of Benzoate in the Management of Seizures in Nonketotic Hyperglycinemia", AJDC, 140: 596-602, 1986.	
	V			

Signature	/Tiffany Gough/	Considered	05/18/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.